ANX-131 is a . It gently reduces the overactive tonic current caused by these Ī“-subunits, allowing the brainās natural phasic (on-demand) inhibition (via Ī±1 and Ī±2 subunits) to work properly again.
But what if there was a third path? Enter , a novel, oral, negative allosteric modulator (NAM) of the GABAA receptor.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. ANX-131 is an investigational drug that has not been approved by the FDA or other global regulatory bodies. By [Your Name/Handle] ANX-131
If Phase 2 data holds up, ANX-131 could be the first oral drug for anxiety since the invention of the benzodiazepine in the 1950s.
In chronic stress and PTSD, the brain doesn't need more inhibition; it needs to restore normal phasic inhibition. Current theories suggest that in anxiety disorders, extrasynaptic receptors (Ī“-subunit containing) become hyperactive, leading to a "tonic" (constant) inhibitory noise that actually destabilizes neural networks. ANX-131 is a
Waitāa negative modulator for anxiety ? That sounds backwards. Here is the clever biophysics: The GABA-A receptor has many subunits. ANX-131 is highly selective for the Ī±4Ī²3Ī“ subunit.
Watch for Phase 2 readouts in late 2027. If successful, this will be a $5 billion molecule within five years of launch. Enter , a novel, oral, negative allosteric modulator
For decades, the treatment of Generalized Anxiety Disorder (GAD) and post-traumatic stress disorder (PTSD) has been a pharmacological balancing act. On one side, you have benzodiazepines (Xanax, Valium)āeffective but highly addictive, with tolerance and withdrawal risks. On the other, you have SSRIs (Zoloft, Prozac)āsafe but slow-acting, with side effects that often make patients quit before they work.